Related Experiment Video
Updated: Oct 7, 2026
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a
B Esteban1, E O'Shea, J Camarero
1Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.
Rationale:
There is good evidence that 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity results from free radical formation. However, it is unclear whether it is the presence of MDMA or a metabolite in the brain that initiates this process.
Objective:
We wished to measure the concentration of MDMA in the brain following peripheral administration of neurotoxic doses and examine the effect on acute monoamine release and the subsequent neurotoxic loss in 5-hydroxytryptamine (5-HT) content when a high concentration of MDMA was infused into cerebral tissue.
Methods:
Selectively placed microdialysis probes were used to determine both the concentration of MDMA in the brain following peripheral injection and the degree of 5-HT release. Monoamines in dialysate and tissue were measured with standard HPLC techniques.
Results:
MDMA, administered intraperitoneally, at doses of 10 and 15 mg/kg, which produce neurodegeneration, resulted in an estimated cerebral extracellular concentration of MDMA of 11 and 20 microM, respectively. When MDMA (100-400 microM) was perfused through a selectively placed microdialysis probe it dose-dependently increased 5-HT release in the hippocampus and dopamine release in the striatum. Seven days after perfusion of MDMA the concentration of 5-HT and its metabolite, 5-hydroxyindoleacetic acid was unchanged in the ipsilateral side of the brain of normothermic rats and also in the brains of animals made hyperthermic to mimic the acute effect of MDMA given peripherally. In contrast, perfusion with 5,7-dihydroxytryptamine (400 microM) markedly decreased the cerebral 5-HT content. A second probe, also placed in the hippocampus at a distance of 1 mm from the main probe, revealed that during the perfusion of MDMA (400 microM) the estimated extracellular concentration of MDMA in the hippocampus was between 10.4 and 19.5 microM, i.e. in the range of concentrations observed after systemic injection of neurotoxic doses of MDMA.
Conclusions:
These data demonstrate that MDMA when injected directly into the brain produces 5-HT release but no neurotoxicity, suggesting that it must be metabolised peripherally in order to produce compounds that induce free radical formation and neurotoxicity in the brain.
Insights
3,4-methylenedioxymethamphetamine (MDMA) directly in the brain causes 5-HT release but no neurotoxicity. Peripheral metabolism of MDMA is necessary to produce toxic compounds that damage brain cells.
Area of Science:
- Neuroscience
- Pharmacology
- Toxicology
Background:
- 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity is linked to free radical formation.
- The precise mechanism initiating MDMA-induced neurotoxicity, whether by MDMA itself or its metabolites in the brain, remains unclear.
Purpose of the Study:
- To quantify brain MDMA concentrations after peripheral administration of neurotoxic doses.
- To assess MDMA's impact on acute monoamine release.
- To investigate the neurotoxic effects on 5-hydroxytryptamine (5-HT) content following direct cerebral infusion of MDMA.
Main Methods:
- Microdialysis probes were employed to measure brain MDMA concentrations and 5-HT release.
- High-performance liquid chromatography (HPLC) was used for quantifying monoamines in dialysate and tissue.
Main Results:
- Peripheral MDMA administration (10-15 mg/kg) led to estimated cerebral MDMA concentrations of 11-20 microM.
- Direct MDMA perfusion (100-400 microM) dose-dependently elevated hippocampal 5-HT and striatal dopamine release.
- No significant changes in 5-HT or its metabolite 5-hydroxyindoleacetic acid were observed in the brain seven days post-MDMA perfusion, unlike the effects of 5,7-dihydroxytryptamine.
Conclusions:
- Direct intracerebral administration of MDMA induces 5-HT release but does not cause neurotoxicity.
- These findings suggest that peripheral metabolism of MDMA is essential for generating the compounds responsible for brain free radical formation and subsequent neurotoxicity.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
01:21Drugs Affecting Neurotransmitter Release or Uptake
01:25Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:24Drug Toxicity: Dose-Dependent Reactions
01:27Adrenergic Neurons: Neurotransmission
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...